HRP20240017T1 - Peptidi - Google Patents
Peptidi Download PDFInfo
- Publication number
- HRP20240017T1 HRP20240017T1 HRP20240017TT HRP20240017T HRP20240017T1 HR P20240017 T1 HRP20240017 T1 HR P20240017T1 HR P20240017T T HRP20240017T T HR P20240017TT HR P20240017 T HRP20240017 T HR P20240017T HR P20240017 T1 HRP20240017 T1 HR P20240017T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- seq
- cell
- mixture
- amino acids
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 4
- 239000000203 mixture Substances 0.000 claims 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. Peptid koji sadrži fragment iz SEK ID BR: 8, pri čemu fragment sadrži najmanje 8 uzastopnih aminokiselina iz SEK ID BR: 8, uključujući najmanje jednu sa položajima 121 i 135 iz SEK ID BR: 8, pri čemu je peptid sposoban da inducira imuni odgovor na mutantni protein TGFβR2 -1a nastao pomicanjem okvira čitanja.
2. Peptid prema patentnom zahtjevu 1, pri čemu fragment sadrži najmanje 9, poželjno najmanje 12, uzastopnih aminokiselina iz SEK ID BR: 8, uključujući najmanje jednu sa položajima 121 i 135 iz SEK ID BR: 8, i/ili pri čemu peptid sadrži ne više od 33 aminokiseline, poželjno ne više od 24 aminokiseline, poželjno ne više od 20 aminokiselina, poželjno ne više od 17 aminokiselina ili poželjno ne više od 9 aminokiselina.
3. Peptid prema patentnom zahtjevu 1 ili 2, pri čemu fragment sadrži položaje 121 do 132 iz SEK ID BR: 8, položaje 129 do 137 iz SEK ID BR: 8 ili položaje 135 do 146 iz SEK ID BR: 8.
4. Peptid prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu aminokiselina koja odgovara položaju 121 ili 135 iz SEK ID BR: 8 je glicin.
5. Peptid prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu peptid sadrži aminokiselinsku sekvencu iz SEK ID BR: 5, SEK ID BR: 7, SEK ID BR: 28 ili SEK ID BR: 30, poželjno pri čemu se peptid sastoji od SEK ID BR: 5, SEK ID BR: 7, SEK ID BR: 28 ili SEK ID BR: 30.
6. Molekula nukleinske kiseline koja kodira peptid kako je definiran u bilo kojem od patentnih zahtjeva 1 do 5.
7. Smjesa peptida koja sadrži prvi i drugi peptid, pri čemu su prvi i drugi peptid, nezavisno, peptidi kako je definirano u bilo kojem od patentnih zahtjeva 1 do 5, i pri čemu je prvi peptid različit od drugog peptida.
8. Vektor koji sadrži molekulu nukleinske kiseline koja sadrži nukleotidnu sekvencu koja kodira peptid kako je definiran u bilo kojem od patentnih zahtjeva 1-5 ili peptidnu smjesu kako je definirana u patentnom zahtjevu 7.
9. Stanica-domaćin koja sadrži vektor kako je definiran u patentnom zahtjevu 8.
10. Netransfektirana T-stanica specifična za peptid kako je definiran u bilo kojem od patentnih zahtjeva 1 do 5.
11. Smjesa T- stanica koja sadrži netransfektirane T- stanice specifične za smjesu peptida kako je definirana u patentnom zahtjevu 7.
12. Farmaceutska kompozicija koja sadrži peptid kako je definiran u bilo kojem od patentnih zahtjeva 1 do 5, molekula nukleinske kiseline kako je definirana u patentnom zahtjevu 6, smjesu peptida kako je definirana u patentnom zahtjevu 7, vektor kako je definiran u patentnom zahtjevu 8, stanicu-domaćina kako je definirana u patentnom zahtjevu 9, netransfektiranu T-stanicu kako je definirana u patentnom zahtjevu 10 ili smjesu T-stanice kako je definirana u patentnom zahtjevu 11, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
13. Peptid kako je definiran u bilo kojem od patentnih zahtjeva 1 do 5, molekula nukleinske kiseline kako je definirana u patentnom zahtjevu 6, smjesa peptida kako je definirana u patentnom zahtjevu 7, vektor kako je definiran u patentnom zahtjevu 8, stanica-domaćin kako je definirana u patentnom zahtjevu 9, T-stanica kako je definirana u patentnom zahtjevu 10, smjesa T-stanica kako je definirana u patentnom zahtjevu 11 ili farmaceutska kompozicija kako je definirana u patentnom zahtjevu 12, za primjenu u liječenju i/ili profilaksi raka, poželjno pri čemu rak je kolorektalni rak ili rak želuca.
14. Postupak odabira peptida, molekula nukleinske kiseline, vektora, stanice-domaćina, smjese peptida, T-stanice, smjese T- stanica ili farmaceutske kompozicije za administriranje pacijentu, koji obuhvaća:
i) identificiranje da li pacijent sa rakom ima mutaciju pomicanja okvira čitanja u TGFβR2 proteinu i ako ima,
ii) odabir peptida kako je definiran u bilo kojem od patentnih zahtjeva 1 do 5, molekula nukleinske kiseline kako je definirana u patentnom zahtjevu 6, smjese peptida kako je definirana u patentnom zahtjevu 7, vektora kako je definiran u patentnom zahtjevu 8, stanice-domaćina kako je definirana u patentnom zahtjevu 9, T-stanice kako je definirana u patentnom zahtjevu 10, smjese T-stanice kako je definirana u patentnom zahtjevu 11 ili farmaceutske kompozicije kako je definirana u patentnom zahtjevu 12.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177444 | 2019-05-29 | ||
| PCT/EP2020/064893 WO2020239937A1 (en) | 2019-05-29 | 2020-05-28 | Peptides |
| EP20728497.7A EP3840767B1 (en) | 2019-05-29 | 2020-05-28 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240017T1 true HRP20240017T1 (hr) | 2024-04-26 |
Family
ID=66677029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240017TT HRP20240017T1 (hr) | 2019-05-29 | 2020-05-28 | Peptidi |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220213170A1 (hr) |
| EP (2) | EP4276463A3 (hr) |
| JP (1) | JP2022535784A (hr) |
| KR (1) | KR20220012938A (hr) |
| CN (1) | CN113891723A (hr) |
| AU (1) | AU2020281912A1 (hr) |
| BR (1) | BR112021023957A2 (hr) |
| CA (1) | CA3141951A1 (hr) |
| CO (1) | CO2021017664A2 (hr) |
| DK (1) | DK3840767T3 (hr) |
| ES (1) | ES2970223T3 (hr) |
| FI (1) | FI3840767T3 (hr) |
| HR (1) | HRP20240017T1 (hr) |
| HU (1) | HUE065269T2 (hr) |
| IL (1) | IL288412A (hr) |
| LT (1) | LT3840767T (hr) |
| MX (1) | MX2021014497A (hr) |
| PL (1) | PL3840767T3 (hr) |
| PT (1) | PT3840767T (hr) |
| SG (1) | SG11202113125QA (hr) |
| SI (1) | SI3840767T1 (hr) |
| WO (1) | WO2020239937A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179221A1 (en) | 2020-05-28 | 2021-12-02 | Hubro Therapeutics As | A peptide cocktail |
| WO2023281117A1 (en) | 2021-07-09 | 2023-01-12 | Hubro Therapeutics As | A Primer |
| EP4223782A1 (en) * | 2022-02-07 | 2023-08-09 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Novel t cell receptors and immune therapy using the same for the treatment of cancer |
| WO2024052542A2 (en) | 2022-09-09 | 2024-03-14 | Hubro Therapeutics As | A peptide cocktail |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| ATE439383T1 (de) * | 2005-09-20 | 2009-08-15 | Peter Jon Nelson | Gewebeinhibitor für metalloproteinasen (timp) gebunden an ein glycosylphosphatidylinositol (gpi-) anker zur behandlung von krebs |
| US8586526B2 (en) * | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| SG183945A1 (en) * | 2010-04-09 | 2012-10-30 | Oncotherapy Science Inc | Cdca5 peptides and vaccines including the same |
| JP2020522477A (ja) * | 2017-06-02 | 2020-07-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 汎用癌ワクチンおよびそれを製造ならびに使用する方法 |
-
2020
- 2020-05-28 HU HUE20728497A patent/HUE065269T2/hu unknown
- 2020-05-28 US US17/614,272 patent/US20220213170A1/en active Pending
- 2020-05-28 SG SG11202113125QA patent/SG11202113125QA/en unknown
- 2020-05-28 CA CA3141951A patent/CA3141951A1/en active Pending
- 2020-05-28 MX MX2021014497A patent/MX2021014497A/es unknown
- 2020-05-28 EP EP23185952.1A patent/EP4276463A3/en active Pending
- 2020-05-28 BR BR112021023957A patent/BR112021023957A2/pt unknown
- 2020-05-28 KR KR1020217042578A patent/KR20220012938A/ko unknown
- 2020-05-28 LT LTEPPCT/EP2020/064893T patent/LT3840767T/lt unknown
- 2020-05-28 CN CN202080039516.0A patent/CN113891723A/zh active Pending
- 2020-05-28 SI SI202030322T patent/SI3840767T1/sl unknown
- 2020-05-28 HR HRP20240017TT patent/HRP20240017T1/hr unknown
- 2020-05-28 EP EP20728497.7A patent/EP3840767B1/en active Active
- 2020-05-28 DK DK20728497.7T patent/DK3840767T3/da active
- 2020-05-28 JP JP2021571354A patent/JP2022535784A/ja active Pending
- 2020-05-28 FI FIEP20728497.7T patent/FI3840767T3/fi active
- 2020-05-28 WO PCT/EP2020/064893 patent/WO2020239937A1/en unknown
- 2020-05-28 PL PL20728497.7T patent/PL3840767T3/pl unknown
- 2020-05-28 AU AU2020281912A patent/AU2020281912A1/en active Pending
- 2020-05-28 PT PT207284977T patent/PT3840767T/pt unknown
- 2020-05-28 ES ES20728497T patent/ES2970223T3/es active Active
-
2021
- 2021-11-25 IL IL288412A patent/IL288412A/en unknown
- 2021-12-22 CO CONC2021/0017664A patent/CO2021017664A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3840767T3 (fi) | 2024-01-31 |
| JP2022535784A (ja) | 2022-08-10 |
| LT3840767T (lt) | 2024-02-26 |
| MX2021014497A (es) | 2022-02-11 |
| KR20220012938A (ko) | 2022-02-04 |
| IL288412A (en) | 2022-01-01 |
| EP4276463A3 (en) | 2024-01-10 |
| PL3840767T3 (pl) | 2024-03-04 |
| EP3840767B1 (en) | 2023-11-15 |
| EP3840767A1 (en) | 2021-06-30 |
| US20220213170A1 (en) | 2022-07-07 |
| SG11202113125QA (en) | 2021-12-30 |
| BR112021023957A2 (pt) | 2022-02-01 |
| EP4276463A2 (en) | 2023-11-15 |
| CN113891723A (zh) | 2022-01-04 |
| AU2020281912A1 (en) | 2022-01-20 |
| CA3141951A1 (en) | 2020-12-03 |
| PT3840767T (pt) | 2024-01-29 |
| CO2021017664A2 (es) | 2022-01-17 |
| DK3840767T3 (da) | 2024-02-12 |
| SI3840767T1 (sl) | 2024-04-30 |
| HUE065269T2 (hu) | 2024-05-28 |
| WO2020239937A1 (en) | 2020-12-03 |
| ES2970223T3 (es) | 2024-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240017T1 (hr) | Peptidi | |
| Lewis et al. | An about 50,000-dalton protein in adrenal medulla: a common precursor of [Met]-and [Leu] enkephalin | |
| Gray et al. | Primary sequence of the alpha-toxin gene from Staphylococcus aureus wood 46 | |
| Laver et al. | Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies | |
| JP2023179436A5 (hr) | ||
| JP4006021B2 (ja) | ケモカインの生物学的活性の強化法 | |
| JP2020534828A5 (hr) | ||
| Fox et al. | Functionally distinct agretopic and epitopic sites. Analysis of the dominant T cell determinant of moth and pigeon cytochromes c with the use of synthetic peptide antigens. | |
| US20180094030A1 (en) | Cell penetrating peptides & methods of identifying cell penetrating peptides | |
| Laine et al. | Complete amino‐acid sequences of DNA‐binding proteins HU‐1 and HU‐2 from Escherichia coli | |
| CA1125282A (en) | D-trp su8 xx-somatostatin analogs | |
| US8110545B2 (en) | Non-proteolysable oligopeptides that inhibit glycoprotein GP41 of the aids virus | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| YU80500A (sh) | Vakcina izazvana sojem virusa hepatitisa b i njeno dobijanje | |
| EP0138616A2 (en) | Nona- and dodecapeptides for augmenting natural killer cell activity, processes for making them and pharmaceutical compositions comprising them | |
| Wissenbach et al. | Physical map location of the new artPIQMJ genes of Escherichia coli, encoding a periplasmic arginine transport system | |
| AU2638295A (en) | Compositions of transactivating proteins of human immunodeficiency virus | |
| EP3392263A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| JPS58206545A (ja) | 免疫調節ペプチド | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| US20160185820A1 (en) | Protransduzin b, a gene transfer enhancer | |
| WO2015072750A1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
| Maryanski et al. | The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized | |
| RU2013115434A (ru) | Пептиды ttll4 и содержащие их вакцины | |
| KR100492820B1 (ko) | 돼지 유행성 설사병 바이러스 중화 에피토프 및 이의 이용 |